6813308766
Longevity Science with Matt Kaeberlein

Advertise on podcast: Longevity Science with Matt Kaeberlein

Rating
★★★★★
5
from
3 reviews
This podcast has
37 episodes
Language
English
Explicit
No
Date created
2026/09/18
Latest episode
2026/11/14
Average duration
48 min.
Release period
8 days

Description

What does the science really say about living longer and staying healthier as we age? On Longevity Science, Matt Kaeberlein—professor, entrepreneur, and longtime leader in the field— explores the biology underlying human and animal healthspan and the interventions that might actually make a difference. From rapamycin and peptides to lifestyle, diagnostics, and emerging therapies like epigenetic reprogramming, this podcast separates signal from noise in a space often dominated by hype. No shortcuts. No miracle cures. Just thoughtful conversations grounded in real science.

Unlock Longevity Science with Matt Kaeberlein podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Longevity Science with Matt Kaeberlein podcast


Longevity Medicine Unfiltered: What Actually Works? | Amy Killen & Kevin White
2026/11/14
What actually works in longevity medicine, and how do we separate meaningful interventions from expensive tests, questionable treatments, and hype?In this special episode of Longevity Science, recorded live at Eudēmonia 2026, Dr. Matt Kaeberlein sits down with Dr. Amy Killen and Dr. Kevin White for an informal, candid, and occasionally humorous conversation about the rapidly evolving world of longevity medicine.Both Amy and Kevin began their careers as emergency medicine physicians before transitioning into preventive and longevity medicine. Drawing on their clinical experience, they share how they approach helping patients improve their healthspan, which diagnostic tests they prioritize, and which interventions they believe offer the greatest potential benefits.The conversation begins with a practical question: If you wanted to optimize your health and longevity, what should you actually measure? From standard blood tests and cardiovascular risk markers to DEXA scans, VO2max, coronary CT angiography, genetic testing, and biological age clocks, we explore which measurements provide actionable information and which may create more confusion than clarity.We also dive into hormone replacement therapy, GLP-1 medications, experimental peptides, growth hormone, and the challenges of balancing promising early evidence with real-world clinical experience.Throughout the discussion, we explore where we agree, where our perspectives differ, and where the science simply isn't mature enough to provide definitive answers.Topics covered include:- Why two emergency physicians transitioned into longevity medicine- What good personalized longevity care should look like- The essential blood tests and biomarkers for evaluating health- VO2max, DEXA, body composition, and cardiovascular screening- Coronary CT angiography (CCTA): Who should consider it?- Whole-body MRI and advanced cancer screening: Benefits, limitations, and false positives- Biological age clocks, microbiome testing, and the problem of actionable information- Are wearables and constant health tracking actually helpful?- Hormone replacement therapy for women during perimenopause and after menopause- GLP-1 medications, microdosing, and potential effects beyond weight loss- The importance of preserving muscle and bone during weight loss- BPC-157, growth hormone secretagogues, and other experimental peptides- What we know—and don't know—about peptide safety and efficacy- The risks of buying unregulated peptides online- Our impressions of Eudēmonia and the current state of the longevity industryAbout the guestsDr. Amy Killen is a physician specializing in longevity medicine, hormone optimization, sexual health, and regenerative therapies. She is co-founder and Chief Medical Officer of Humanaut and author of The Female Longevity Advantage.Dr. Kevin White is a physician and former emergency medicine doctor who now focuses on personalized preventive and longevity medicine, helping patients identify and address risk factors for age-related disease.About Longevity ScienceHosted by Dr. Matt Kaeberlein, Longevity Science explores the biology of aging and the emerging science of extending human healthspan. Through conversations with leading scientists, physicians, and innovators, we examine the evidence behind longevity interventions and distinguish established science from speculation and hype.Subscribe for more evidence-based conversations about aging, health, and longevity.Disclaimer: This podcast is intended for educational and informational purposes only and does not constitute medical advice. Some interventions discussed are experimental, investigational, or used off-label. Clinical experiences and anecdotal observations should not be interpreted as proof of safety or efficacy. Always consult a qualified healthcare professional before making medical decisions.
The Epigenetic Secret Behind Why Big Dogs Age Faster
2026/11/10
Why do Great Danes typically live much shorter lives than Chihuahuas? Do larger dogs actually age faster, or do they simply die younger?In this special presentation from the Animal Longevity Summit (ALOS), Dr. Noah Snyder-Mackler explores these questions through groundbreaking new research from the Dog Aging Project, recently published in Science.In his lecture, "Epigenetic Mechanisms of Size-Related Lifespan Compression," Noah presents evidence that larger dogs experience accelerated age-related changes in DNA methylation, particularly in regions of the genome containing transposable elements, sometimes called "jumping genes."Using more than 1,600 DNA methylation profiles from approximately 900 companion dogs, researchers found that:Larger dogs show evidence of accelerated epigenetic aging compared with smaller dogs.Dogs with higher epigenetic ages relative to their chronological ages have an increased risk of mortality.Age-associated DNA methylation changes are amplified in larger dogs, especially in regions containing transposable elements.Loss of DNA methylation at certain LINE-1 transposable elements may point toward molecular mechanisms contributing to size-related differences in lifespan.Could the loss of epigenetic regulation of jumping genes help explain why large dogs age faster? And what might these findings teach us about the fundamental biology of aging in humans?Importantly, while these findings identify compelling molecular associations, they do not yet establish that transposable element activation causes accelerated aging or shorter lifespan.This presentation offers a fascinating look at how the Dog Aging Project is using the remarkable diversity of companion dogs to uncover biological mechanisms of aging, with the ultimate goal of helping both dogs and people live longer, healthier lives.About the speakerDr. Noah Snyder-Mackler is a professor in the Center for Evolutionary Medicine at Arizona State University. He studies the molecular, evolutionary, and social determinants of health and aging. His laboratory leads important work on the epigenetics of aging within the Dog Aging Project.About this presentationThis lecture was originally delivered at the Animal Longevity Summit (ALOS) and is shared on Longevity Science with Matt Kaeberlein with Dr. Snyder-Mackler's permission.Scientific publication"Epigenetic aging and transposon dysregulation reflect size-related lifespan compression in dogs." Science (2026).Learn moreDog Aging Project: https://dogagingproject.orgDog Aging Institute: https://dogaginginstitute.orgSubscribe to Longevity Science with Matt Kaeberlein for evidence-based conversations about the biology of aging, longevity interventions, and the science of extending healthspan.#LongevityScience #DogAgingProject #Epigenetics #DogLongevity #AgingResearch DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.
Can a Centenarian Gene Slow Aging? The SIRT6 Gene Therapy Story
2026/11/05
What if a gene variant found in people who live past 100 could help us develop therapies to slow aging?In this episode of Longevity Science, I sit down with Dr. Eric Leire, CEO of Genflow Biosciences, to explore the science behind SIRT6, a gene involved in DNA repair, metabolism, and several fundamental processes associated with aging.Eric and I discuss Genflow's approach to delivering a human centenarian-associated SIRT6 variant through gene therapy, including results from a preliminary study in 24 older beagle dogs. The study reported encouraging signals in muscle-related measurements and epigenetic aging markers, but important questions remain about statistical significance, biological mechanisms, and whether these findings will be reproducible and translate into meaningful improvements in health or lifespan.We also explore some of the broader challenges facing longevity biotechnology, including how to interpret epigenetic clocks, the importance of rigorous clinical trials, and the tension between scientific evidence and the hype surrounding emerging longevity interventions.Topics we cover:What SIRT6 does and why it matters for aging biologyThe discovery of a SIRT6 variant associated with human centenariansEvidence that SIRT6 overexpression can extend lifespan in miceHow Genflow's gene therapy works and why the company chose to study aging dogsResults from the first 24-dog study, including muscle measurements and epigenetic aging clocksWhy promising preliminary findings aren't proof of efficacyThe limitations of first-generation epigenetic clocks as measures of biological agingWhat additional experiments are needed to establish whether SIRT6 gene therapy actually worksThe potential for translating these findings into treatments for age-related muscle loss and other conditions in humansThe challenges of communicating early scientific results without overselling them This conversation is an opportunity to explore both the promise and the uncertainty with someone working to bring longevity gene therapy into the clinic.About the guest:Dr. Eric Leire is CEO of Genflow Biosciences, a biotechnology company developing gene therapies based on a human centenarian-associated variant of SIRT6. The company is investigating potential applications in aging-related conditions, including sarcopenia, glaucoma, and metabolic disease.About Longevity Science:Hosted by Dr. Matt Kaeberlein, Longevity Science explores the biology of aging and the scientific evidence behind interventions that may help us live longer, healthier lives. Through conversations with leading researchers, clinicians, and innovators, we separate promising science from speculation and hype.Subscribe for more evidence-based conversations about aging, healthspan, and longevity medicine.#LongevityScience #SIRT6 #GeneTherapy #Longevity #AgingResearch #Healthspan #DogAging #GeroscienceDISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.
The Story of the Dog Aging Project: How One Dog Changed Longevity Science
2026/11/03
Can we slow aging in dogs and help them live longer, healthier lives? More than a decade ago, that question inspired the creation of the Dog Aging Project, which has grown from an ambitious idea into one of the largest studies of aging ever conducted in companion animals, with more than 55,000 dogs participating.In this special presentation from the inaugural Animal Longevity Summit, Dr. Matt Kaeberlein shares the personal story behind the Dog Aging Project, beginning with his German Shepherd, Dobby, and the realization that discoveries from laboratory aging research might someday help our own dogs live longer.Matt takes us through the project's history, from the first clinical trials of rapamycin in dogs to the challenges of building and sustaining a large-scale scientific effort. He also highlights some of the most interesting discoveries from the project and provides an update on TRIAD, the ongoing randomized, placebo-controlled clinical trial testing whether rapamycin can extend lifespan and improve healthspan in companion dogs.Topics covered include:How Dobby inspired Matt to pursue longevity research in dogsThe origins and evolution of the Dog Aging ProjectHow more than 55,000 dogs are helping scientists understand agingSurprising associations between feeding frequency and age-related diseaseWhat we're learning about canine dementia and brain agingWhy large dogs age faster but may not experience faster cognitive declineThe science behind rapamycin as a potential longevity interventionThe design and progress of the TRIAD rapamycin clinical trialThe future of companion animal longevity research and therapeuticsThe Dog Aging Project was founded on the belief that companion dogs offer a unique opportunity to understand the biology of aging—and, more importantly, to translate that knowledge into interventions that could give us more healthy years with the animals we love.As the field of animal longevity continues to grow, the lessons from the Dog Aging Project may also help shape the future of human longevity medicine.Learn more:Dog Aging Project: https://dogagingproject.orgDog Aging Institute: https://dogaginginstitute.orgSubscribe to Longevity Science with Matt Kaeberlein for evidence-based discussions of aging biology, longevity interventions, and the science of living longer and healthier.About the speaker:Matt Kaeberlein, PhD, is a scientist specializing in the biology of aging, co-founder of the Dog Aging Project, and President and Co-Founder of the Dog Aging Institute. His research has focused on understanding the mechanisms of biological aging and developing interventions to improve healthspan and lifespan.This presentation was recorded at the inaugural Animal Longevity Summit in 2026. The TRIAD trial remains ongoing and blinded; whether rapamycin extends lifespan in companion dogs has not yet been established.#DogAgingProject #LongevityScience #DogLongevity #Rapamycin #HealthyAging #Geroscience #AnimalLongevity
Can Rapamycin Reverse Skin Aging? The Science of Skin Rejuvenation
2026/11/02
Can rapamycin reverse skin aging?In this episode of Longevity Science, I sit down with Dr. Chris Sell and Dr. Christina Chung, co-founders of Hayflick Therapeutics, to explore the science behind using rapamycin to target aging in the skin.Chris has spent decades studying cellular senescence, IGF signaling, mTOR, and rapamycin. Christina is a dermatologist whose work with transplant patients gave her a very different perspective on rapamycin and its effects on skin biology. Their paths eventually converged around a fascinating question: could targeting mTOR with topical rapamycin actually improve the function and appearance of aging human skin?We discuss the early experiments showing that rapamycin can extend the replicative lifespan of human cells, what happens when mTOR remains active in senescent cells, and how Chris and Christina moved from basic science to a controlled human study of topical rapamycin. We also talk about why skin may be an underappreciated organ in geroscience, the difference between scientifically rigorous skin rejuvenation and the enormous amount of hype in the aesthetics industry, and why Hayflick is pursuing the much more difficult path of FDA approval.More broadly, this conversation gets at one of the biggest challenges facing geroscience: how do we translate interventions that affect fundamental mechanisms of aging into therapies that can actually be tested, approved, and used in people?Disclosure: I serve on the Scientific Advisory Board (SAB) of Hayflick Therapeutics. This relationship is disclosed so viewers can appropriately consider any potential conflict of interest. The discussion reflects my own views and is intended for scientific and educational purposes.Topics include: rapamycin and mTOR, cellular senescence, the Hayflick limit, skin aging and rejuvenation, topical rapamycin, transplant dermatology, FDA drug development, and translating geroscience into human medicine.DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram: https://www.instagram.com/mkaeberlein/LinkedIn: https://www.linkedin.com/in/mkaeberlein/Twitter: https://twitter.com/mkaeberleinFacebook: https://www.facebook.com/matt.kaeberlein/
Peptides, Astronauts, and AI: Lessons from the First 10,000 Longevity Experiments at Ora Biomedical
2026/10/06
What can we learn from the first 10,000 experiments in the search for interventions that extend healthy lifespan?In this episode of Longevity Science, I sit down with Dr. Ben Blue, CEO of Ora Biomedical, and Dr. Blair Zhao, CSO, for an update on Ora’s effort to systematically screen interventions for effects on lifespan and healthspan.We start with the Million Molecule Challenge and some intriguing new results from a screen of roughly 300 peptides, including known peptides, AI-predicted candidates, and structurally diverse molecules. We discuss what Ora is beginning to learn from nearly 10,000 intervention experiments, why existing datasets may not be sufficient to predict longevity therapeutics with AI, and how large-scale experimental data could eventually change that. We also explore an unexpected direction emerging from these experiments: resilience. Rather than asking only whether a molecule extends lifespan, can longevity interventions improve the body's ability to recover from damage? That question has led Ora from lifespan studies in C. elegans to UV and radiation resistance, human skin cells, animal studies, and potential applications ranging from photoaging and cancer radiation therapy to protecting pilots and astronauts from radiation exposure. Along the way, Ben and Blair share early results from Ora’s pipeline, including a longevity-associated compound that reduced radiation dermatitis burden by approximately 40% in a mouse model, as well as work on natural products that may improve recovery from UV damage. We also discuss the challenge of translating discoveries from worms into humans and whether resilience could provide a practical path for testing longevity therapeutics on a much shorter timescale. Disclosure: I am a co-founder of Ora Biomedical and serve on its Board of Directors. I have a financial interest in the company. This relationship is disclosed so viewers can appropriately consider this potential conflict of interest when evaluating the discussion.Topics include: the Million Molecule Challenge, AI and longevity drug discovery, peptide therapeutics, C. elegans, mTOR, stress resilience, UV damage, radiation therapy, skin aging, natural products, astronauts and spaceflight, and translating longevity interventions to humans.DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram: https://www.instagram.com/mkaeberlein/LinkedIn: https://www.linkedin.com/in/mkaeberlein/Twitter: https://twitter.com/mkaeberleinFacebook: https://www.facebook.com/matt.kaeberlein/
Longevity Roundtable: GLP-1s, Statins, Aging Clocks & Right to Try
2026/09/25
In this episode of Longevity Roundtable for September 2026, I’m joined by Brian Kennedy and Marcus Ranney to dig into some of the biggest recent stories in longevity science and medicine.We start with Marcus fresh off a high-altitude marathon and discuss intermittent hypoxia, hyperoxia, and hyperbaric oxygen therapy. From there, we take a close look at the new mouse lifespan data on semaglutide and what it does, and doesn’t, tell us about GLP-1 drugs and biological aging. We also discuss concerns about GLP-1s and vision loss, and how to think about potential risks in the context of their demonstrated benefits.Then we turn to new evidence linking statin use with reduced dementia risk, the persistent concern that lowering cholesterol could negatively affect the brain, and what the evidence actually suggests.We also tackle a recent Nature Medicine study asking whether epigenetic aging clocks respond to longevity interventions. Can these clocks really tell us whether an intervention is slowing biological aging? And what should we make of the fact that interventions like exercise and rapamycin don't necessarily move them in the direction we might expect?Finally, we discuss Montana’s new Right to Try framework for experimental therapies, why I agreed to serve on its review board, and whether new regulatory models could generate useful clinical data while giving patients greater access to experimental treatments. And, naturally, we finish with Bryan Johnson—because apparently no Longevity Roundtable is complete without him.Topics include: GLP-1 agonists and lifespan, semaglutide, intermittent hypoxia, hyperbaric oxygen, statins and dementia, cholesterol and brain health, epigenetic aging clocks, rapamycin, Right to Try, experimental medicine, and the future of longevity science.DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram: https://www.instagram.com/mkaeberlein/LinkedIn: https://www.linkedin.com/in/mkaeberlein/Twitter: https://twitter.com/mkaeberleinFacebook: https://www.facebook.com/matt.kaeberlein/
Building a Resilient Brain with Dr. Tommy Wood
2026/09/18
What can we actually do to protect our brains as we age, and how much of cognitive decline may be preventable or even reversible?In this episode of Longevity Science, I sit down with neuroscientist and physician Dr. Tommy Wood, author of The Stimulated Mind, for a wide-ranging conversation about the science of brain health, cognitive resilience, and dementia risk. Tommy introduces his “3S” framework—stimulus, support, and supply—for thinking about what the brain needs to maintain and improve function across the lifespan.We discuss why brain fog and subjective cognitive decline shouldn't simply be dismissed as normal aging; the roles of cognitive stimulation, exercise, sleep, stress, metabolic and cardiovascular health; and what the evidence actually says about supplements including creatine, magnesium, omega-3s, vitamin D, multivitamins, and lithium. We also dig into pharmaceuticals and emerging approaches, including statins and PCSK9 inhibitors, GLP-1 agonists, PDE5 inhibitors, TMS and other forms of brain stimulation, and psychedelics such as psilocybin.Perhaps most importantly, we talk about reasons for optimism. Age-specific dementia incidence has declined over recent decades, and we already know much more about maintaining cognitive function than many people realize. The challenge now is figuring out how to combine what we know into strategies that help people build a more resilient brain—and maintain it for life.Topics include: brain fog and cognitive decline, dementia prevention, neuroplasticity, sleep and stress, exercise, cardiovascular and metabolic health, supplements for brain health, creatine, lithium, GLP-1 drugs, brain stimulation, psychedelics, and the future of dementia treatment.DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram: https://www.instagram.com/mkaeberlein/LinkedIn: https://www.linkedin.com/in/mkaeberlein/Twitter: https://twitter.com/mkaeberleinFacebook: https://www.facebook.com/matt.kaeberlein/
Magic Mushrooms for Longevity? The Surprising Science of Psilocybin and Aging
2026/09/11
What if the effects of psilocybin extend far beyond the brain and into the biology of aging itself?In this episode of Longevity Science, I sit down with Dr. Louise Hecker and Dr. Kosuke Kato, whose unexpected research on psilocybin has opened up a fascinating new question: Could psilocybin actually influence longevity?Their work started with a simple experiment. Treat aging cells with psilocin, the active metabolite of psilocybin, and see what happens. The result was a striking, dose-dependent extension of cellular replicative lifespan. They then took the much bigger step of testing psilocybin in aged mice, where treatment produced a surprisingly large survival benefit during the period they were permitted to follow the animals.We dig into those findings, the important limitations of the mouse experiment, and what they are learning about how psilocybin may be affecting aging biology. Intriguingly, some of the strongest effects appear to occur outside the brain, including persistent changes in inflammatory and immune pathways across multiple organs. Louise and Kosuke also share new details about their work with microdosing, effects on aging skin and hair in mice, non-psychedelic psilocybin derivatives, and efforts to develop topical formulations. One particularly interesting question is whether the potential effects on aging require the psychedelic experience at all, or whether the two can ultimately be separated.And perhaps most excitingly, this research is now moving into humans. Louise and collaborators are performing a Phase 1 clinical trial, which will test full psychedelic doses of psilocybin in healthy adults ages 60–85 and examine biological aging markers along with other measures of health and function.We also talk about why psilocybin research remains surprisingly limited, the challenges of doing rigorous science with a Schedule I drug, and the important distinction between recreational psychedelic use and studying psilocybin as a potential medicine.There is still a long way to go before anyone can say that psilocybin slows aging in humans. But the early findings are intriguing, and they're raising some fascinating questions about psychedelics, inflammation, cellular aging, and longevity.In this episode:🍄 How a conversation about magic mushrooms led to a longevity experiment🧬 Psilocin, cellular senescence, and telomeres🐭 What happened when aged mice received psilocybin🔥 Psilocybin's surprising effects on inflammation🧠 Does the psychedelic experience matter for longevity?💊 Microdosing versus full psychedelic doses🧴 Aging skin, hair, and topical psilocybin derivatives🔬 Parallels between psilocybin and rapamycin👨‍⚕️ The first human trial of psilocybin for healthy aging⚠️ What the science does—and doesn't—justify today#Psilocybin #Longevity #MagicMushrooms #Psychedelics #Aging #LongevityScience #GeroscienceDISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.
Did rapamycin cause Bryan Johnson's autoimmune disease?
2026/09/09
Bryan Johnson recently announced that he has been diagnosed with autoimmune gastritis, an autoimmune condition that, in his words, means his “stomach is eating itself.”So what does this have to do with rapamycin?Bryan took rapamycin for about four years before stopping it, attributing changes in his lipids, blood glucose, resting heart rate, and soft-tissue infections to the drug. But given the hundreds of other interventions in his protocol, can we actually know that rapamycin was responsible?In this episode of Longevity Science, I look at what we actually know about Bryan’s diagnosis, his history of autoimmune thyroid disease, and the biology of rapamycin and sterile inflammation.There’s also an interesting twist: rapamycin is a potent suppressor of sterile inflammation, and there is evidence suggesting that it may be beneficial in some autoimmune and inflammatory conditions. So if rapamycin played any role in Bryan’s autoimmune disease, is it possible that stopping it was more important than taking it?I also discuss a larger problem illustrated by Bryan’s experiment-of-one: when you’re taking dozens of drugs, supplements, and other interventions while constantly changing the protocol, it becomes nearly impossible to confidently attribute an outcome—good or bad—to any single intervention.The point isn’t that rapamycin caused Bryan’s disease, or that stopping rapamycin caused it. We simply don’t know. The point is that speculation shouldn’t be presented as scientific certainty.And there may be an even bigger lesson here: despite spending enormous resources on health optimization and being perhaps the “most measured man on Earth,” a significant medical condition appears to have gone undetected for years. #Rapamycin #BryanJohnson #Longevity #LongevityScience #AutoimmuneDisease #AgingDISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.
Longevity for Dogs: Our Sentinels for Human Aging?
2026/09/06
Subscribe to our channel: https://www.youtube.com/@mkaeberleinWhat can dogs teach us about human aging?Quite a lot, it turns out.Dogs share our homes, our environments, and many of the same age-related diseases, but they experience aging over a much shorter timescale. That makes companion dogs a uniquely powerful population for understanding why individuals age differently and, potentially, how we might extend healthy lifespan in both dogs and people.In this episode, I’ve pulled together some of my favorite moments from three recent conversations on the Longevity for Dogs podcast with Dr. Noah Snyder-Mackler, Dr. Evan MacLean, and Dr. Audrey Ruple.We explore some fascinating, and sometimes surprising, questions:Can epigenetic clocks tell us how quickly a dog is aging?Why do large dogs live much shorter lives than small dogs, yet seem to age cognitively at about the same rate?What can canine dementia teach us about Alzheimer’s disease?How important are social connection and social isolation for healthy aging?Can dogs serve as “sentinels” for environmental risks that also affect humans?What do we actually know about diet, exercise, obesity, and healthy longevity in dogs?And could we someday dramatically extend healthy canine lifespan?One of the things I find most exciting about this work is that we don’t have to choose between improving human health and improving animal health. By studying aging in companion dogs, we have an opportunity to learn fundamental biology that may ultimately help both species live longer, healthier lives.These conversations originally appeared on Longevity for Dogs, a podcast from the nonprofit Dog Aging Institute. If you enjoy this episode, check out the full conversations and other episodes exploring the science of canine aging and longevity.https://www.youtube.com/@LongevityForDogsGuests:Dr. Noah Snyder-Mackler — Arizona State UniversityDr. Evan MacLean — University of ArizonaDr. Audrey Ruple — Virginia TechDISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.
Longevity CAGE MATCH: Science Takes on Hype
2026/09/05
Every now and then, a claim in longevity gets so far ahead of the evidence that it deserves a little pushback.This time, the catalyst was a recent video from Longevity Science News that claimed a newly published Nature Communications paper had essentially reversed skin aging and even suggested it proved me wrong.So... I decided to have a little fun with it.Consider this the Longevity Cage Match: scientist versus stand-up comedian. (For the record, I have nothing against stand-up comedians. I do have something against overselling science.)In this video I walk through what the paper actually shows and where the LSN video goes off the rails:• What the new CMLase enzyme really accomplished• Why removing one type of molecular damage is not the same as reversing aging• How the paper used directed evolution (and where AI actually fits into the story)• Why "40 years of damage removed" makes for a great thumbnail but a poor scientific conclusion• The difference between a genuinely exciting proof-of-principle and a breakthrough therapyThe study is actually a very nice piece of work. I say that repeatedly. It's clever, well executed, and potentially important. But good science deserves to be celebrated for what it actually shows, not for what we'd like it to show.The longevity field already struggles with exaggerated headlines, miracle claims, and snake oil. We don't need to invent breakthroughs when the real science is interesting enough on its own.As always, I'd love to hear your thoughts in the comments. If you think I've misunderstood the paper, point me to the data. If you agree, let me know where you think the line is between enthusiasm and hype.Either way, let's keep the discussion intellectually honest and evidence-based.Paper discussed:Trabosh et al. Reversal of protein chemical aging by enzymatic deglycation. Nature Communications (2026).
Longevity Science Update: The Biggest Stories in Longevity Medicine — July 2026
2026/07/31
What are the biggest developments in longevity medicine right now?In this Longevity Science Update, Dr. Marcus Ranney and I discuss the most important stories shaping the field—from changes to FDA policy on experimental peptides to the tragic death following an NAD infusion, the approval of the first oral PCSK9 inhibitor, the latest on GLP-1 drugs, and what the evidence actually says about intermittent fasting.Rather than chasing headlines, we examine what these developments mean in the context of the current scientific evidence—and where important questions remain.In this episode:FDA committee recommendations on compounded peptidesWhat the recent NAD infusion death means for longevity medicineThe first oral PCSK9 inhibitor and cardiovascular disease preventionAre GLP-1 drugs true longevity therapeutics?Retatrutide and the next generation of obesity drugsNAD precursors: what do we actually know?Diet quality vs. calorie restriction vs. intermittent fastingNew developments in India's longevity ecosystemWhether you're a clinician, researcher, or simply interested in healthy aging, this monthly update is designed to help you stay informed with an evidence-based perspective.Subscribe for future Longevity Science Updates, interviews with leading scientists, and discussions on the biology of aging and evidence-based approaches to extending healthspan.#Longevity #HealthyAging #GLP1 #Peptides #NAD #PCSK9 #HeartHealth #LongevityScience #AgingResearch #HealthspanDISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram: https://www.instagram.com/mkaeberlein/LinkedIn: https://www.linkedin.com/in/mkaeberlein/Twitter: https://twitter.com/mkaeberleinFacebook: https://www.facebook.com/matt.kaeberlein/---
Irina Conboy Says We've Been Measuring Aging All Wrong
2026/07/30
For years, Irina Conboy has been one of the most influential scientists studying how aging is regulated by factors circulating in the blood. Her pioneering work on heterochronic parabiosis helped reshape the way researchers think about aging, rejuvenation, and the biology of systemic signaling.In this episode of Longevity Science, I sit down with Irina and Alina Rui Su, co-founders of Generation Lab, to discuss their latest research, their new approach to understanding biological aging, and why they believe many of today's epigenetic "aging clocks" are measuring the wrong thing.We explore the evidence behind parabiosis, plasma dilution, and circulating aging factors before diving into Generation Lab's concept of epigenetic instability as a fundamental driver of biological aging. We also discuss their efforts to develop a new biological age assessment and a therapeutic approach they hope can simultaneously reduce age-related inflammation and promote tissue regeneration.Along the way, Irina and I have a spirited—but friendly—scientific debate about rapamycin, biological age testing, and what it will take to demonstrate that any intervention truly slows human aging.Whether you agree with every conclusion or not, this is exactly the kind of scientific discussion that moves the field forward.In this episode:Irina Conboy's journey from academia to founding Generation LabWhat decades of parabiosis research have taught us about agingWhy young blood may not be the answerPlasma dilution and therapeutic plasma exchangeThe role of circulating factors in age-related declineWhy Generation Lab believes current epigenetic clocks are fundamentally limitedA new approach to understanding biological aging through epigenetic instabilityThe science behind Generation Lab's proposed therapeutic strategyA scientific debate on rapamycin and longevity interventionsWhat it will take to prove that a therapy truly slows human agingAs always, the goal of Longevity Science is to examine the evidence critically. Some of the ideas discussed in this episode remain hypotheses under active investigation and have not yet been validated in large human clinical trials.If you enjoy thoughtful conversations about the science of healthy aging, subscribe for future interviews with the researchers who are shaping the field.#longevity #aging #biologicalage #rapamycin #parabiosis #epigenetics #healthspan #plasmadilution #generationlab #irinaconboyDISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram:   / mkaeberlein  LinkedIn:   / mkaeberlein  Twitter:   / mkaeberlein  Facebook:   / matt.kaeberlein
The Pill That Could Prevent Heart Disease
2026/07/26
A new era in cholesterol lowering may have just begun.In this episode of Longevity Science, I take a deep dive into enlicitide, the first FDA-approved oral PCSK9 inhibitor. If you've been following my recent videos, you know I started taking Repatha (evolocumab) after a coronary CT angiography (CCTA) with contrast revealed early soft plaque in my coronary arteries. Repatha has reduced my LDL cholesterol and ApoB by more than 50%, but many people would prefer a pill over injections.That's where enlicitide comes in.I'll explain how this new drug works, how it compares to injectable PCSK9 inhibitors like Repatha, and what we know—and don't yet know—about its safety and effectiveness.In this episode, you'll learn:• What PCSK9 does and why inhibiting it dramatically lowers LDL and ApoB • How enlicitide differs from Repatha • Why enlicitide is a macrocyclic peptide, and what that actually means • What clinical trials have shown so far • The advantages and disadvantages of oral versus injectable PCSK9 inhibitors • Why cardiovascular outcomes data still matter, even when LDL lowering is impressive • Whether I plan to switch from Repatha to enlicitide Although enlicitide appears to lower LDL cholesterol by a similar magnitude to Repatha, it was approved based on its ability to reduce LDL-C—not because it has yet demonstrated reductions in heart attacks or other cardiovascular events. Those studies are ongoing, and that's an important distinction when evaluating a new therapy.Overall, I think this is an exciting advance in cardiovascular medicine. Giving patients a choice between an injection and a daily pill has the potential to improve adherence and make one of our most effective approaches to reducing cardiovascular risk accessible to many more people.If you missed my previous episode explaining why I decided to start Repatha—and why a CCTA with contrast may provide far more useful information than a calcium scan alone—be sure to check that out as well.As always, this video is intended for educational purposes only and should not be considered medical advice. Talk with your healthcare provider before making decisions about your own treatment.If you enjoyed this episode, please like, subscribe, and let me know your thoughts or questions in the comments below.DISCLAIMER: The information provided on this channel is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.More places to find me:Instagram: https://www.instagram.com/mkaeberlein/LinkedIn: https://www.linkedin.com/in/mkaeberlein/Twitter: https://twitter.com/mkaeberleinFacebook: https://www.facebook.com/matt.kaeberlein/

Podcast reviews

Read Longevity Science with Matt Kaeberlein podcast reviews


5 out of 5
3 reviews

Podcast sponsorship advertising

Start advertising on Longevity Science with Matt Kaeberlein relevant audience podcasts


What do you want to promote?